Medicines Approved for Specific Cancers (M to Z)

Drugs Approved for Malignant Mesothelioma

Pemetrexed

Drugs Approved for Melanoma

Aldesleukin

Binimetinib

Cobimetinib

Dabrafenib

Dacarbazine

Encorafenib

Ipilimumab

Nivolumab

Peginterferon Alfa-2b

Pembrolizumab

Recombinant Interferon Alfa-2b

Talimogene Laherparepvec

Trametinib

Vemurafenib

Drugs Approved for Multicentric Castleman Disease

Siltuximab

Drugs Approved for Multiple Myeloma and Other Plasma Cell Neoplasms

Bortezomib

Carfilzomib

Carmustine

Cyclophosphamide

Daratumumab

Doxorubicin

Elotuzumab

Ixazomib

Lenalidomide

Melphalan

Melphalan

Pamidronate

Panobinostat

Plerixafor

Pomalidomide

Thalidomide

Zoledronic Acid

Drugs Approved for Myeloproliferative Neoplasms

Arsenic Trioxide

Azacitidine

Cyclophosphamide

Cytarabine

Dasatinib

Daunorubicin

Decitabine

Doxorubicin

Imatinib

Nilotinib

Ruxolitinib

Drugs Approved for Neuroblastoma

Cyclophosphamide

Dinutuximab

Doxorubicin

Vincristine

Drugs Approved for Non-Hodgkin’s Lymphoma

Drugs Approved for Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Bevacizumab

Carboplatin

Cisplatin

Cyclophosphamide

Doxorubicin

Gemcitabine

Melphalan

Niraparib

Olaparib

Paclitaxel

Rucaparib

Thiotepa

Topotecan

Drugs Approved for Pancreatic Cancer

Erlotinib

Everolimus

Fluorouracil

Gemcitabine

Irinotecan

Mitomycin C

Paclitaxel

Sunitinib

Drugs Approved for Penile Cancer

Bleomycin

Drugs Approved for Prostate Cancer

Abiraterone

Apalutamide

Bicalutamide

Cabazitaxel

Degarelix

Docetaxel

Enzalutamide

Flutamide

Goserelin

Leuprolide

Mitoxantrone

Nilutamide

Radium 223 Dichloride

Sipuleucel-T

Drugs Approved for Rectal Cancer

Bevacizumab

Capecitabine

Cetuximab

Fluorouracil

Ipilimumab

Irinotecan

Leucovorin

Nivolumab

Oxaliplatin

Panitumumab

Pembrolizumab

Ramucirumab

Regorafenib

Trifluridine and Tipiracil Hydrochloride

Ziv-Aflibercept

Drugs Approved for Retinoblastoma

Cyclophosphamide

Drugs Approved for Rhabdomyosarcoma

Dactinomycin

Vincristine

Drugs Approved for Melanoma

Aldesleukin

Cobimetinib

Dabrafenib

Dacarbazine

Ipilimumab

Nivolumab

Peginterferon Alfa-2b

Pembrolizumab

Recombinant Interferon Alfa-2b

Talimogene Laherparepvec

Trametinib

Vemurafenib

Drugs Approved for Merkel Cell Carcinoma

Avelumab

Pembrolizumab

Drugs Approved for Basal Cell Carcinoma

Fluorouracil

Imiquimod

Sonidegib

Vismodegib

Drugs Approved for Cutaneous Squamous Cell Carcinoma

Cemiplimab-rwlc

Drugs Approved for Soft Tissue Sarcoma

Dactinomycin

Doxorubicin

Eribulin

Imatinib

Olaratumab

Pazopanib

Trabectedin

Drugs Approved for Stomach Cancer

Docetaxel

Doxorubicin

Fluorouracil

Mitomycin C

Pembrolizumab

Ramucirumab

Trastuzumab

Trifluridine and Tipiracil Hydrochloride

Drugs Approved for Testicular Cancer

Bleomycin

Cisplatin

Dactinomycin

Etoposide

Ifosfamide

Vinblastine

Drugs Approved for Thyroid Cancer

Cabozantinib

Vandetanib

Dabrafenib

Doxorubicin

Lenvatinib

Sorafenib

Trametinib

Vandetanib

Drugs Approved for Vulvar Cancer

Bleomycin

Drugs Approved for Wilms Tumor

Dactinomycin

Dactinomycin

Doxorubicin

Vincristine

Other Cancers

Medicines Approved for Specific Cancers (A-D)

Medicines Approved for Specific Cancers (E-L)